Call Us Now813-323-5448

Email us Directoricos@gmail.com

Patient Resources Become a Member Renew Membership Make a Donation Member Login

December 2020 : Cardiac dysfunction in a patient treated with cabozantinib.

What do we know about cardiotoxicity of VEGF-inhibitors?

Presenters: Sebastian Szmit, MD, PhD (cardio-oncologist) & Michał Wilk, MD
Department of Oncology, Centre of Postgraduate Medical Education, Warsaw, Poland

Monthly Webinars, 2020-Monthly Webinars

You may also like

February 2021 : Optimizing Cancer Survivorship and Cardiovascular outcomes: Gaps and opportunities

February 2021 : Optimizing Cancer Survivorship and Cardiovascular outcomes: Gaps and opportunities

November 2020: Lung cancer patient with pembrolizumab

November 2020: Lung cancer patient with pembrolizumab

October 2020 ICOS Monthly Case Study Webinar

October 2020 ICOS Monthly Case Study Webinar

September 2020 ICOS Monthly Case Study Webinar

September 2020 ICOS Monthly Case Study Webinar

August 2020 : A case of acute and rapidly progressive RV failure

August 2020 : A case of acute and rapidly progressive RV failure

July 2020 Carcinoid Heart Disease secondary to Neuroendocrine Tumors (NET)

July 2020 Carcinoid Heart Disease secondary to Neuroendocrine Tumors (NET)

June 2020: Capecitabine-induced Hypertriglyceridemia: Case Report and Topic Review.

June 2020: Capecitabine-induced Hypertriglyceridemia: Case Report and Topic Review.

May 2020 -“The Promise and Pitfalls of Continuing Trastuzumab in the Presence of Cardiotoxicity”

May 2020 -“The Promise and Pitfalls of Continuing Trastuzumab in the Presence of Cardiotoxicity”

April 2020 Case Review: "Is Oral Chemotherapy Really Safer than IV Chemotherapy? An Osemertinib Cardiotoxicity Case"

April 2020 Case Review: “Is Oral Chemotherapy Really Safer than IV Chemotherapy? An Osemertinib Cardiotoxicity Case”

Dr. Geeta Gulati, Department of Cardio Oncology, Oslo University Hospital, Ullevaal, Norway "The difficulty of troponin elevation during treatment with check point inhibitors

Dr. Geeta Gulati, Department of Cardio Oncology, Oslo University Hospital, Ullevaal, Norway “The difficulty of troponin elevation during treatment with check point inhibitors

February 2020 : Special Cardio-Oncology Considerations in Patients with Genetic Syndromes

February 2020 : Special Cardio-Oncology Considerations in Patients with Genetic Syndromes

January 2020 : Treating the Treatment: Multi-Organ Toxicities of Fluoropyrimidines and Platinum-based Combination Therapies

January 2020 : Treating the Treatment: Multi-Organ Toxicities of Fluoropyrimidines and Platinum-based Combination Therapies

12 3…8 »

Page 1 of 8